2023-07-12 03:48:00
Bioplus-Interpex Korea 2023 was held at COEX in Gangnam-gu, Seoul with the theme of ‘Revamping the Industry’.
The global comprehensive bio convention ‘Bioplus-Interpex Korea 2023 (hereinafter referred to as BIX 2023)’ was held at COEX, Gangnam-gu, Seoul on the 12th and 14th.
BIX 2023 is co-hosted by the Korea Bio Association and RX Korea. ‘Revamping the Industry’ is the theme. This event consists of ▲conference ▲corporate exhibition ▲partnering ▲open innovation stage. In particular, a docent tour will be introduced for the first time this year as a side event.
The opening ceremony was attended by the Ministry of Trade, Industry and Energy and about 400 officials. Korea Bio Association Chairman Koh Han-seung (Samsung Bioepis CEO), Bio Association Chairman Lim Jung-bae (Daesang Representative), RX Korea CEO Son Joo-beom attended. In addition, overseas VIPs included Nancy Travis, International Cooperation Officer of the Bio Association of America (BIO), and Litvia Minister of Economic Affairs Japan Indrixone.
Ko Han-seung, president of the association, said, “The theme of this year’s conference was ‘Revamping the industry’ in the sense of overcoming difficult situations in the past few years and moving forward.” It is organized so that you can meet the entire value chain of bio-healthcare, including bio, in one place.”
BIX 2023 also has a place where participating companies and visitors can hold business meetings with each other.
Participation of the largest CDMO companies in the world
In BIX 2023, not only domestic companies but also many other companies participate. Representatively, ▲Lonza ▲Wuxi Biologics ▲Fujifilm, etc., and SK Bioscience, ESTGENBIO, Kolon, Daewoong Pharmaceutical, Medipost, GC Cell, etc. will attend.
Consignment development and manufacturing is a word in which development is added to CMO, which means consignment manufacturing. Why are pharmaceutical companies interested in CDMO? This is because of the advantage of being able to cooperate with global pharmaceutical and bio companies and being provided with capabilities and platforms for new drug development.
In addition, CDMO experienced a shortage of medicines worldwide due to the COVID-19 pandemic, and pharmaceutical companies’ demand for global manufacturers that can supply medicines without a hitch increased. According to Frost & Sullivan, a global market company, the global bio CDMO market is expected to reach $47.7 billion in 2028 (approximately KRW 61.56 trillion).
An industry insider who attended the exhibition said, “It is unusual for many companies to gather in one place after COVID-19.” It was a meaningful place,” he said.
Lonza ranks first in CDMO sales worldwide. In the COVID-19 situation, it collaborated with Moderna, and in April of this year, it signed a contract with domestic company ABL Bio for new bispecific antibody candidates. At this BIX 2023, it plans to promote the technology and safety of its CDMO and attract customers.
The same goes for Fujifilm. Since 2006, Fujifilm has expanded its business into the bio and healthcare sectors by building biotechnology capabilities through active M&A. Currently, Fujifilm’s bio CDMO subsidiary, Fujifilm Diosynth Biotechnologies (FDB), recorded sales of 194 billion yen (approximately 1.9 trillion won) last year. Fujifilm currently has a bioreactor production capacity of 240,000 liters and plans to add 160,000 liters by 2026 through a $1.6 billion investment project.
Lee Seung-gyu, Vice Chairman of the Korea Bio Association, said, “A large number of global CDMO companies, including Korea, China, and Japan, attended BIX2023.” As leading companies in domestic CMO and CDMO gathered in one place, they plan to actively publicize the strengths of Korea.”he emphasized.
BIX 2023 has prepared a docent program, a special group tour introduced for the first time this year to support more professional exhibition viewing for visitors.
Conference, you can find out the global biopharmaceutical regulation trend
The highlight of BIX2023 is a conference attended by various companies and countries.
The conference is held in the conference room on the 3rd floor of COEX and is divided into keynote sessions, professional sessions, and corporate sessions.
on the 12th ▲Current status of the Korean bio industry and future direction ▲Current status of the Latin American biopharmaceutical market ▲Rapidly emerging platform technology ADC, PROTAC & carrier ▲K-BIO 2023 bio issue TOP7 that the media paid attention to ▲Answers for global clinical trials for bio companies Sessions on ‘global pharmaceutical and bio trends’ are prepared.
On the 13th, the second day, ▲Biden’s executive order, the impact of the Korean bio economy & Bio USA 2023 debriefing ▲Guidance on new FDA inspection regulations for pharmaceutical manufacturers, etc. We plan to learn about ‘regulatory trends in the US’. In addition, there are also sessions on future biotechnology such as microbiome, dementia treatment, and Egritech.
On the last day, the 14th, pharmaceutical company trends and future visions will be announced. For example, in ‘CEOs Born in the 1990s’, business philosophy and leadership for success are introduced through the entrepreneurial stories of CEOs born in the 1990s, the MZ generation. In addition, ‘New Drug Development and Partnering in the Digital Era’ will introduce the DHT program, the latest initiative related to FDA product development related to digital health technology, by Sidley Law Firm, a U.S. law firm.
Meanwhile, at BIX 2023, for the first time this year, you can experience cold chain logistics through the docent program, a special group tour introduced to support more professional exhibition viewing for visitors. Docent is on the 14th from 12:40 to 13:30 Cold Chain Platform CCP CEO Kim Hee-yang explains industry trends and the latest technology trends in the industry.
© Health Trend Unauthorized reproduction and redistribution prohibited
1689136941
#BioplusInterpex #Korea #held #CDMO #FDA #regulations #glance